HOMA-IR Calculator

How to Use This Calculator

1. Enter fasting glucose (mg/dL) and fasting insulin (mIU/L) — both must be true fasting values (≥8 hours).
2. HOMA-IR and insulin resistance category display instantly.
3. SI Units tab: enter glucose in mmol/L for international users.
4. Professional tier adds HOMA-β, QUICKI, HbA1c context, and metabolic syndrome risk assessment.

Formula

Example

Frequently Asked Questions

• What is HOMA-IR? ▼
  HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a mathematical model developed by Matthews et al. in 1985 at the University of Oxford to estimate insulin resistance from fasting glucose and fasting insulin levels. The model is based on the feedback loop between the pancreatic beta cells (which secrete insulin) and the liver (which is the primary site of insulin-mediated glucose suppression). In the HOMA1 model, the calculation uses simple linear relationships: HOMA-IR = (Fasting Insulin in mIU/L × Fasting Glucose in mg/dL) / 405, or equivalently HOMA-IR = (Insulin × Glucose in mmol/L) / 22.5. The index quantifies how much insulin is required to maintain normal fasting glucose — a person with insulin resistance needs more insulin to maintain the same glucose level, resulting in higher HOMA-IR. A HOMA-IR of 1 is defined as the normal value for a lean, young, healthy reference population. Values below 1 indicate high insulin sensitivity; values from 1–2.5 indicate mild insulin resistance; 2.5–5 represents significant insulin resistance associated with prediabetes, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease risk; values above 5 indicate severe insulin resistance. HOMA-IR is a single fasting sample test, making it practical for epidemiological studies and clinical screening, though it measures only hepatic insulin resistance, not peripheral (muscle) insulin resistance.
• What HOMA-IR value indicates insulin resistance? ▼
  There is no single universal HOMA-IR threshold for insulin resistance because the cutoff varies by study population, ethnicity, age, and the clinical context. However, the most widely referenced thresholds are: HOMA-IR <1.0 — normal insulin sensitivity, seen in lean healthy individuals; 1.0–2.5 — mild insulin resistance, found in many overweight adults and some with metabolic risk factors; 2.5–5.0 — significant insulin resistance, strongly associated with prediabetes (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and polycystic ovary syndrome (PCOS); above 5.0 — severe insulin resistance, commonly found in established type 2 diabetes, advanced NAFLD/NASH, and severe metabolic syndrome. Population-specific cutoffs: in some South Asian and Hispanic populations, lower HOMA-IR thresholds (≥2.0) are used because these groups develop T2DM at lower BMI and HOMA-IR levels. In pediatric populations, HOMA-IR thresholds are generally higher (resistance cutoffs of 3.16–4.39 in pubertal children due to physiological pubertal insulin resistance). For the Diabetes Prevention Program (DPP), participants had a median HOMA-IR of ~3.6 at enrollment. Lifestyle intervention reducing HOMA-IR by ~0.5–1.0 units is achievable with moderate weight loss (5–7%) and correlated with a 58% reduction in T2DM incidence over 3 years.
• How is HOMA-IR different from HOMA-β? ▼
  HOMA-IR and HOMA-β are companion indices from the same original HOMA model but measure different aspects of pancreatic and hepatic function. HOMA-IR measures insulin resistance (the degree to which cells resist the action of insulin), calculated as (Insulin × Glucose) / 405 in mg/dL units. HOMA-β measures pancreatic beta cell function (the capacity of beta cells to secrete insulin in response to glucose), calculated as (20 × Insulin) / (Glucose in mmol/L − 3.5), expressed as a percentage of normal. In a healthy, lean reference individual, HOMA-β = 100% by convention. Clinical implications: in early type 2 diabetes and prediabetes, HOMA-IR rises first (insulin resistance precedes beta cell failure), while HOMA-β may be normal or even elevated (compensatory hyperinsulinemia). As diabetes progresses, HOMA-β falls as beta cells become exhausted. In type 1 diabetes, HOMA-β is very low (<20%) due to autoimmune beta cell destruction, while HOMA-IR may be normal. Tracking both HOMA-IR and HOMA-β over time provides a more complete picture of the natural history of T2DM: rising HOMA-IR → beta cell compensation (elevated HOMA-β) → beta cell exhaustion (falling HOMA-β) → overt T2DM. In clinical practice, HOMA-β is less commonly used than HOMA-IR but can be valuable in longitudinal studies of diabetes prevention interventions.
• Should I use HOMA1 or HOMA2? ▼
  HOMA1 (the original 1985 model) uses the simple linear formula described above and is the version used in most clinical calculators, research papers, and MDCalc. HOMA2 is a computer-based model developed by Wallace et al. (2004, Diabetes Care) at Oxford that incorporates non-linear relationships, accounts for variations in hepatic and peripheral insulin resistance, and adjusts for renal glucose clearance at higher glucose levels, as well as C-peptide as an alternative insulin secretion marker. HOMA2 is more accurate than HOMA1 at glucose values above 180 mg/dL (10 mmol/L) and at high insulin levels, where the linear HOMA1 model becomes less valid. For practical clinical use with most patients (fasting glucose 70–180 mg/dL, insulin 2–30 mIU/L), HOMA1 and HOMA2 give very similar results — typically within 10–15% of each other. HOMA2 requires the HOMA Calculator software (freely available from the University of Oxford) or specific spreadsheet implementations. The vast majority of published research uses HOMA1 because it is calculable by hand or simple formula, facilitating comparison across studies. For research involving populations with diabetes, obesity, or extreme insulin levels, HOMA2 is preferred. For general clinical use and population screening, HOMA1 is perfectly adequate. The key practical point: whichever version you use, report it consistently and compare only with reference populations using the same model.
• Can I lower my HOMA-IR with lifestyle changes? ▼
  Yes — HOMA-IR is highly responsive to lifestyle interventions, and this is one of its most clinically important applications as a monitoring tool for treatment response. The most effective strategies for reducing HOMA-IR are: (1) Weight loss: each 5% reduction in body weight reduces HOMA-IR by approximately 20–30%. The Diabetes Prevention Program demonstrated that a 7% weight loss through diet and exercise reduced HOMA-IR significantly and cut T2DM incidence by 58% over 3 years. (2) Exercise: both aerobic exercise and resistance training independently improve insulin sensitivity. A meta-analysis by Strasser et al. showed that resistance training reduced HOMA-IR by ~0.50 and aerobic exercise by ~0.29 on average. Combined exercise produces the largest effects. Even moderate-intensity walking (150 minutes/week, as recommended by ADA) produces meaningful HOMA-IR reductions. (3) Dietary changes: reducing refined carbohydrates and saturated fat, increasing fiber (whole grains, vegetables, legumes), and following Mediterranean-style eating patterns all reduce HOMA-IR. The low-glycemic-index diet and DASH diet have demonstrated HOMA-IR reductions of 0.3–1.0 in RCTs. (4) Sleep improvement: poor sleep and obstructive sleep apnea are associated with insulin resistance; treatment of OSA (CPAP) and sleep hygiene improvements reduce HOMA-IR. (5) Pharmacological: metformin, GLP-1 receptor agonists (semaglutide, liraglutide), and SGLT2 inhibitors all reduce HOMA-IR, with GLP-1 agonists showing the largest effects in obese patients.

Related Calculators